JP2022513029A5 - - Google Patents

Info

Publication number
JP2022513029A5
JP2022513029A5 JP2021526256A JP2021526256A JP2022513029A5 JP 2022513029 A5 JP2022513029 A5 JP 2022513029A5 JP 2021526256 A JP2021526256 A JP 2021526256A JP 2021526256 A JP2021526256 A JP 2021526256A JP 2022513029 A5 JP2022513029 A5 JP 2022513029A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
inhibitor
seq
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021526256A
Other languages
English (en)
Japanese (ja)
Other versions
JP7513604B2 (ja
JP2022513029A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/061212 external-priority patent/WO2020102375A1/en
Publication of JP2022513029A publication Critical patent/JP2022513029A/ja
Publication of JP2022513029A5 publication Critical patent/JP2022513029A5/ja
Priority to JP2024102591A priority Critical patent/JP7904269B2/ja
Application granted granted Critical
Publication of JP7513604B2 publication Critical patent/JP7513604B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021526256A 2018-11-14 2019-11-13 皮膚がんを治療するためのpd-1阻害剤の病変内投与 Active JP7513604B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024102591A JP7904269B2 (ja) 2018-11-14 2024-06-26 皮膚がんを治療するためのpd-1阻害剤の病変内投与

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862767218P 2018-11-14 2018-11-14
US62/767,218 2018-11-14
PCT/US2019/061212 WO2020102375A1 (en) 2018-11-14 2019-11-13 Intralesional administration of pd-1 inhibitors for treating skin cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024102591A Division JP7904269B2 (ja) 2018-11-14 2024-06-26 皮膚がんを治療するためのpd-1阻害剤の病変内投与

Publications (3)

Publication Number Publication Date
JP2022513029A JP2022513029A (ja) 2022-02-07
JP2022513029A5 true JP2022513029A5 (cg-RX-API-DMAC7.html) 2022-11-07
JP7513604B2 JP7513604B2 (ja) 2024-07-09

Family

ID=68841191

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021526256A Active JP7513604B2 (ja) 2018-11-14 2019-11-13 皮膚がんを治療するためのpd-1阻害剤の病変内投与
JP2024102591A Active JP7904269B2 (ja) 2018-11-14 2024-06-26 皮膚がんを治療するためのpd-1阻害剤の病変内投与

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024102591A Active JP7904269B2 (ja) 2018-11-14 2024-06-26 皮膚がんを治療するためのpd-1阻害剤の病変内投与

Country Status (16)

Country Link
US (2) US12473364B2 (cg-RX-API-DMAC7.html)
EP (2) EP3880186B1 (cg-RX-API-DMAC7.html)
JP (2) JP7513604B2 (cg-RX-API-DMAC7.html)
CN (1) CN113038939A (cg-RX-API-DMAC7.html)
DK (1) DK3880186T3 (cg-RX-API-DMAC7.html)
ES (1) ES2980363T3 (cg-RX-API-DMAC7.html)
FI (1) FI3880186T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20240825T1 (cg-RX-API-DMAC7.html)
HU (1) HUE067601T2 (cg-RX-API-DMAC7.html)
LT (1) LT3880186T (cg-RX-API-DMAC7.html)
PL (1) PL3880186T3 (cg-RX-API-DMAC7.html)
PT (1) PT3880186T (cg-RX-API-DMAC7.html)
RS (1) RS65627B1 (cg-RX-API-DMAC7.html)
SI (1) SI3880186T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202400252T1 (cg-RX-API-DMAC7.html)
WO (1) WO2020102375A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI680138B (zh) * 2014-01-23 2019-12-21 美商再生元醫藥公司 抗pd-l1之人類抗體
ES2954153T3 (es) 2015-12-22 2023-11-20 Regeneron Pharma Combinación de anticuerpos anti-PD-1 y anticuerpos biespecíficos anti-CD20/anti-CD3 para tratar el cáncer
CN116134155A (zh) * 2020-08-26 2023-05-16 瑞泽恩制药公司 通过施用pd-1抑制剂治疗癌症的方法
JP2024511106A (ja) * 2021-03-23 2024-03-12 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Pd-1阻害剤を投与することにより免疫抑制または免疫不全患者におけるがんを処置する方法

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2539411T3 (es) 1999-08-23 2015-06-30 Dana-Farber Cancer Institute, Inc. PD-1, receptor para la B7-4 y su utilización
DE60334303D1 (de) 2002-07-03 2010-11-04 Tasuku Honjo Immunpotenzierende zusammensetzungen
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
US7563869B2 (en) 2003-01-23 2009-07-21 Ono Pharmaceutical Co., Ltd. Substance specific to human PD-1
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
CA2698419C (en) 2007-09-07 2019-11-12 Ablynx N.V. Binding molecules with multiple binding sites, compositions comprising the same and uses thereof
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
EA201500417A1 (ru) 2008-08-25 2015-11-30 Эмплиммьюн, Инк. Композиции антагонистов pd-1 и способы применения
WO2010036959A2 (en) 2008-09-26 2010-04-01 Dana-Farber Cancer Institute Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
TW201134488A (en) 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
US9163087B2 (en) 2010-06-18 2015-10-20 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against TIM-3 and PD-1 for immunotherapy in chronic immune conditions
US8686119B2 (en) 2011-07-24 2014-04-01 Curetech Ltd. Variants of humanized immunomodulatory monoclonal antibodies
BR112014012819B1 (pt) 2011-11-28 2022-08-16 Merck Patent Gmbh Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
HUE037659T2 (hu) 2012-03-16 2018-09-28 Regeneron Pharma Hisztidinmódosított könnyûlánc antitestek és genetikailag módosított rágcsálók ennek az elõállítására
US9175082B2 (en) 2012-05-31 2015-11-03 Sorrento Therapeutics, Inc. Antigen binding proteins that bind PD-L1
ES2742379T3 (es) 2012-05-31 2020-02-14 Hoffmann La Roche Procedimientos de tratamiento del cáncer usando antagonistas de unión al eje de PD-1 y antagonistas de VEGF
US9308236B2 (en) 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對pd-1的人類抗體
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗pd-l1之人類抗體
US10092645B2 (en) 2014-06-17 2018-10-09 Medimmune Limited Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy
SG10201901057UA (en) 2014-08-05 2019-03-28 Cb Therapeutics Inc Anti-pd-l1 antibodies
MA42971A (fr) 2015-03-13 2018-08-15 Cytomx Therapeutics Inc Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation
JP6295998B2 (ja) 2015-05-12 2018-03-20 株式会社デンソー 内燃機関の再始動制御装置
MX383464B (es) 2015-07-13 2025-03-14 Cytomx Therapeutics Inc Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y métodos de uso de los mismos.
AR105654A1 (es) 2015-08-24 2017-10-25 Lilly Co Eli Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
JP6869987B2 (ja) 2015-09-01 2021-05-12 アジェナス インコーポレイテッド 抗pd−1抗体及びその使用方法
CN108495651A (zh) 2015-12-17 2018-09-04 诺华股份有限公司 抗pd-1的抗体分子及其用途
ES2954153T3 (es) 2015-12-22 2023-11-20 Regeneron Pharma Combinación de anticuerpos anti-PD-1 y anticuerpos biespecíficos anti-CD20/anti-CD3 para tratar el cáncer
CA3011460A1 (en) 2016-01-15 2017-07-20 Rfemb Holdings, Llc Immunologic treatment of cancer
IL261998B2 (en) 2016-04-07 2023-03-01 Chemocentryx Inc Reducing your burden by giving ccr1 antagonists in combination with pd-1 inhibitors or pd-l1 inhibitors
TWI822521B (zh) 2016-05-13 2023-11-11 美商再生元醫藥公司 藉由投予pd-1抑制劑治療皮膚癌之方法
IL307242B1 (en) 2016-12-07 2026-07-01 Agenus Inc Anti-CTLA-4 antibodies and methods of using them
CN117442719A (zh) 2017-02-21 2024-01-26 瑞泽恩制药公司 用于治疗肺癌的抗pd-1抗体
US10166290B2 (en) 2017-02-24 2019-01-01 Max H. Cohen Intralesional (Intratumoral) dinitrochlorobenzene and associated compounds coadministered with checkpoint inhibitors for cancer treatment including treatment of metastatic cutaneous cancers
US11603407B2 (en) 2017-04-06 2023-03-14 Regeneron Pharmaceuticals, Inc. Stable antibody formulation
AU2018287317B2 (en) 2017-06-19 2024-06-20 Medicenna Therapeutics Inc. Uses and methods for IL-2 superagonists, agonists, and fusions thereof

Similar Documents

Publication Publication Date Title
JP5823874B2 (ja) 抗CD30vc−PAB−MMAE抗体−薬物コンジュゲートのウィークリー投与計画
JP2019515008A5 (cg-RX-API-DMAC7.html)
CN111065411A (zh) Pd-1抗体和vegfr抑制剂联合治疗小细胞肺癌的用途
JP2020508317A5 (cg-RX-API-DMAC7.html)
JP2021528423A5 (cg-RX-API-DMAC7.html)
CN111132696B (zh) Pd-1抗体和表观遗传调节剂联合在制备治疗肿瘤的药物中的用途
WO2018223923A1 (zh) Pd-1抗体与vegf配体或vegf受体抑制剂联合在制备治疗肿瘤的药物中的用途
RU2006120950A (ru) Антитело к cd40: препарат и способы
FI3880186T3 (fi) PD-1-inhibiittoreiden intralesionaalinen antaminen ihosyövän hoitamiseksi
HK1213782A1 (zh) 在诊断和治疗类风湿性关节炎中使用的包含抗-cd6单克隆抗体的药物组合物
JP2015500822A5 (cg-RX-API-DMAC7.html)
JP2024534602A5 (cg-RX-API-DMAC7.html)
JP2024527607A5 (cg-RX-API-DMAC7.html)
JP2023520771A5 (cg-RX-API-DMAC7.html)
IL278400B2 (en) Combination of an anti pd-1 antibody and anti tissue factor (tf) antibody drug conjugate for use in the treatment of cancer
JP2023507795A5 (cg-RX-API-DMAC7.html)
TWI870592B (zh) 使用免疫檢查點抑制劑抗體治療癌症之方法和組合
JP2022530599A5 (cg-RX-API-DMAC7.html)
JP2025509567A5 (cg-RX-API-DMAC7.html)
JP7159007B2 (ja) 脳腫瘍の治療のための医薬
CN111166878A (zh) 靶向肿瘤抗原的抗体与iNKT细胞的组合的制备方法与用途
RU2020133811A (ru) Фармацевтические комбинации
JP2023500480A5 (cg-RX-API-DMAC7.html)
CN112955148B (zh) Cdk4/6抑制剂联合免疫治疗在制备治疗淋巴瘤的药物中的用途
CN110013552B (zh) 抗pd-1抗体、吉西他滨和铂类药物联合治疗恶性胆道肿瘤的用途